CZ192998A3 - 2,7-Substituované oktahydropyrrolo[1,2-a]pyrazinové deriváty, meziprodukty pro jejich výrobu a farmaceutické prostředky na jejich bázi - Google Patents
2,7-Substituované oktahydropyrrolo[1,2-a]pyrazinové deriváty, meziprodukty pro jejich výrobu a farmaceutické prostředky na jejich bázi Download PDFInfo
- Publication number
- CZ192998A3 CZ192998A3 CZ981929A CZ192998A CZ192998A3 CZ 192998 A3 CZ192998 A3 CZ 192998A3 CZ 981929 A CZ981929 A CZ 981929A CZ 192998 A CZ192998 A CZ 192998A CZ 192998 A3 CZ192998 A3 CZ 192998A3
- Authority
- CZ
- Czechia
- Prior art keywords
- pyrazine
- octahydropyrrolo
- substituted
- pharmaceutically acceptable
- formula
- Prior art date
Links
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical class C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 title claims description 39
- 238000002360 preparation method Methods 0.000 title claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 24
- 239000000543 intermediate Chemical class 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 269
- -1 benzoxazolonyl Chemical group 0.000 claims abstract description 176
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 40
- 208000035475 disorder Diseases 0.000 claims abstract description 39
- 229960003638 dopamine Drugs 0.000 claims abstract description 31
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 17
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 13
- 125000001041 indolyl group Chemical group 0.000 claims abstract description 7
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 6
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract description 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims abstract description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims abstract description 4
- 125000005493 quinolyl group Chemical group 0.000 claims abstract description 4
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 3
- 125000002541 furyl group Chemical group 0.000 claims abstract description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims abstract description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims abstract description 3
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 92
- 241000124008 Mammalia Species 0.000 claims description 42
- 230000002265 prevention Effects 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 26
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical class CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 14
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 13
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 239000000460 chlorine Chemical group 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 12
- 125000004212 difluorophenyl group Chemical group 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 12
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 10
- 208000028017 Psychotic disease Diseases 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- 208000016285 Movement disease Diseases 0.000 claims description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 208000019116 sleep disease Diseases 0.000 claims description 8
- 201000009032 substance abuse Diseases 0.000 claims description 8
- 208000011117 substance-related disease Diseases 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims description 7
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 239000003176 neuroleptic agent Substances 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 208000022873 Ocular disease Diseases 0.000 claims description 5
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 208000017194 Affective disease Diseases 0.000 claims description 4
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 4
- 208000016620 Tourette disease Diseases 0.000 claims description 4
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 230000027119 gastric acid secretion Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 231100000736 substance abuse Toxicity 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 208000019553 vascular disease Diseases 0.000 claims description 4
- MUNPRJATIUVQNI-VHSXEESVSA-N (7r,8as)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-ol Chemical compound C([C@@H]1C[C@H](CN1CC1)O)N1C1=NC=C(F)C=N1 MUNPRJATIUVQNI-VHSXEESVSA-N 0.000 claims description 3
- JGRLEYKBYBFXAU-SQJZIBIZSA-N 3-[[(7S,8aS)-2-(5-chloropyridin-2-yl)-1-methyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl]oxy]benzonitrile Chemical compound C(#N)C=1C=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=C3)Cl)C2)C=CC=1 JGRLEYKBYBFXAU-SQJZIBIZSA-N 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- HKHFOBZOYABVDH-WDEREUQCSA-N (7r,8as)-2-(5-chloropyridin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-ol Chemical compound C([C@@H]1C[C@H](CN1CC1)O)N1C1=CC=C(Cl)C=N1 HKHFOBZOYABVDH-WDEREUQCSA-N 0.000 claims description 2
- KTNLKNZYVOELFG-ROUUACIJSA-N (7s,8as)-2-(5-chloropyridin-2-yl)-7-[(4-fluorophenyl)methoxy]-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1CO[C@@H]1CN2CCN(C=3N=CC(Cl)=CC=3)C[C@@H]2C1 KTNLKNZYVOELFG-ROUUACIJSA-N 0.000 claims description 2
- MUNPRJATIUVQNI-UWVGGRQHSA-N (7s,8as)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-ol Chemical compound C([C@@H]1C[C@@H](CN1CC1)O)N1C1=NC=C(F)C=N1 MUNPRJATIUVQNI-UWVGGRQHSA-N 0.000 claims description 2
- QZBFYGAAFDCAEF-IRXDYDNUSA-N (7s,8as)-7-[(4-fluorophenyl)methoxy]-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1CO[C@@H]1CN2CCN(C=3N=CC(F)=CN=3)C[C@@H]2C1 QZBFYGAAFDCAEF-IRXDYDNUSA-N 0.000 claims description 2
- BDEDALBTQRDSGO-ROUUACIJSA-N 3-[[(7s,8as)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-yl]oxymethyl]benzonitrile Chemical compound N1=CC(F)=CN=C1N1C[C@@H]2C[C@H](OCC=3C=C(C=CC=3)C#N)CN2CC1 BDEDALBTQRDSGO-ROUUACIJSA-N 0.000 claims description 2
- SSZLEWUDHUIKLO-SQJZIBIZSA-N 4-[[(7S,8aS)-2-(5-chloropyridin-2-yl)-1-methyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl]oxy]benzonitrile Chemical compound C(#N)C1=CC=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=C3)Cl)C2)C=C1 SSZLEWUDHUIKLO-SQJZIBIZSA-N 0.000 claims description 2
- QSLLFYVBWXWUQT-UHFFFAOYSA-N 7-Azaindolizine Chemical class C1=NC=CN2C=CC=C21 QSLLFYVBWXWUQT-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 4
- LHBPTLBPEMRINB-JQWIXIFHSA-N [(7s,8as)-2-(5-chloropyridin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-yl]methanol Chemical compound C([C@@H]1C[C@@H](CN1CC1)CO)N1C1=CC=C(Cl)C=N1 LHBPTLBPEMRINB-JQWIXIFHSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 abstract description 13
- 102000015554 Dopamine receptor Human genes 0.000 abstract description 13
- 239000003446 ligand Substances 0.000 abstract description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102000003962 Dopamine D4 receptors Human genes 0.000 abstract 1
- 108090000357 Dopamine D4 receptors Proteins 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 142
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 92
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 84
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 77
- 239000000243 solution Substances 0.000 description 74
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 71
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 62
- 238000000034 method Methods 0.000 description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 239000002904 solvent Substances 0.000 description 49
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 48
- 239000000203 mixture Substances 0.000 description 48
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 46
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 44
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 31
- 235000019341 magnesium sulphate Nutrition 0.000 description 31
- 239000000741 silica gel Substances 0.000 description 31
- 229910002027 silica gel Inorganic materials 0.000 description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 30
- 238000003818 flash chromatography Methods 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 239000002585 base Substances 0.000 description 25
- 238000000746 purification Methods 0.000 description 25
- 239000000706 filtrate Substances 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 24
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 24
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- 229910000029 sodium carbonate Inorganic materials 0.000 description 22
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 20
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 20
- 230000008569 process Effects 0.000 description 20
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 19
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 229910000104 sodium hydride Inorganic materials 0.000 description 15
- 239000012312 sodium hydride Substances 0.000 description 15
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 239000012280 lithium aluminium hydride Substances 0.000 description 13
- 239000002798 polar solvent Substances 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 239000003638 chemical reducing agent Substances 0.000 description 12
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 10
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 125000005270 trialkylamine group Chemical group 0.000 description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 9
- 239000012442 inert solvent Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000011593 sulfur Chemical group 0.000 description 9
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 230000001476 alcoholic effect Effects 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 239000007900 aqueous suspension Substances 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 150000004678 hydrides Chemical class 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229910000510 noble metal Inorganic materials 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- AGYUQBNABXVWMS-UHFFFAOYSA-N 2-chloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1 AGYUQBNABXVWMS-UHFFFAOYSA-N 0.000 description 6
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 6
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 6
- 150000008041 alkali metal carbonates Chemical class 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- SPZOQWFGOKWGFZ-UHFFFAOYSA-N 2-benzyl-7-[(4-fluorophenoxy)methyl]-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1OCC1CN2CCN(CC=3C=CC=CC=3)CC2C1 SPZOQWFGOKWGFZ-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 5
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 239000004533 oil dispersion Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 4
- LMRDBJZQDUVCQH-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetaldehyde Chemical compound C1=CC=C2C(=O)N(CC=O)C(=O)C2=C1 LMRDBJZQDUVCQH-UHFFFAOYSA-N 0.000 description 4
- RISLNIIGHKRBKI-UHFFFAOYSA-N 7-[(4-fluorophenoxy)methyl]-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1OCC1CN2CCNCC2C1 RISLNIIGHKRBKI-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- ITNLRLZNAQIFKI-YUMQZZPRSA-N [(7s,8as)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazin-7-yl]methanol Chemical compound C1NCCN2C[C@@H](CO)C[C@H]21 ITNLRLZNAQIFKI-YUMQZZPRSA-N 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 125000005604 azodicarboxylate group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 4
- 229960003987 melatonin Drugs 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UCBVGPJTDOAYPO-UHFFFAOYSA-N (2-benzyl-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-yl)methanol Chemical compound C1CN2CC(CO)CC2CN1CC1=CC=CC=C1 UCBVGPJTDOAYPO-UHFFFAOYSA-N 0.000 description 3
- VLVMRQREBYGIBY-NKWVEPMBSA-N (7r,8as)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazin-7-ol Chemical compound C1NCCN2C[C@H](O)C[C@H]21 VLVMRQREBYGIBY-NKWVEPMBSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001879 copper Chemical class 0.000 description 3
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 125000006575 electron-withdrawing group Chemical group 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- NRSBQSJHFYZIPH-IMJSIDKUSA-N (2s,4s)-4-carboxypyrrolidin-1-ium-2-carboxylate Chemical compound OC(=O)[C@@H]1CN[C@H](C(O)=O)C1 NRSBQSJHFYZIPH-IMJSIDKUSA-N 0.000 description 2
- AFHWQRAGGBADBN-UONOGXRCSA-N (7r,8as)-2-benzyl-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-ol Chemical compound C([C@@H]1C[C@H](CN1CC1)O)N1CC1=CC=CC=C1 AFHWQRAGGBADBN-UONOGXRCSA-N 0.000 description 2
- HKHFOBZOYABVDH-QWRGUYRKSA-N (7s,8as)-2-(5-chloropyridin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-ol Chemical compound C([C@@H]1C[C@@H](CN1CC1)O)N1C1=CC=C(Cl)C=N1 HKHFOBZOYABVDH-QWRGUYRKSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- GCTFDMFLLBCLPF-UHFFFAOYSA-N 2,5-dichloropyridine Chemical compound ClC1=CC=C(Cl)N=C1 GCTFDMFLLBCLPF-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- UIFZMZQUVALRHQ-STQMWFEESA-N 6-[(7s,8as)-7-(hydroxymethyl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl]pyridine-3-carbonitrile Chemical compound C([C@@H]1C[C@@H](CN1CC1)CO)N1C1=CC=C(C#N)C=N1 UIFZMZQUVALRHQ-STQMWFEESA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 2
- 102000004076 Dopamine D1 Receptors Human genes 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- KREGKYQIUMOXGH-ONGXEEELSA-N [(7s,8as)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-yl]methanol Chemical compound C([C@@H]1C[C@@H](CN1CC1)CO)N1C1=NC=C(F)C=N1 KREGKYQIUMOXGH-ONGXEEELSA-N 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910010277 boron hydride Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000009084 cardiovascular function Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 208000031424 hyperprolactinemia Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- UQPPKZJMIXQOJD-BQBZGAKWSA-N methyl (7s,8as)-1-oxo-3,4,6,7,8,8a-hexahydro-2h-pyrrolo[1,2-a]pyrazine-7-carboxylate Chemical compound C1CNC(=O)[C@H]2N1C[C@@H](C(=O)OC)C2 UQPPKZJMIXQOJD-BQBZGAKWSA-N 0.000 description 2
- VUMKANWHKKDOBW-UHFFFAOYSA-N methyl 2-benzyl-1-oxo-3,4,8,8a-tetrahydropyrrolo[1,2-a]pyrazine-7-carboxylate Chemical compound O=C1C2CC(C(=O)OC)=CN2CCN1CC1=CC=CC=C1 VUMKANWHKKDOBW-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000810 peripheral vasodilating agent Substances 0.000 description 2
- 229960002116 peripheral vasodilator Drugs 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- ZZJYIKPMDIWRSN-TZBSWOFLSA-N (+)-butaclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 ZZJYIKPMDIWRSN-TZBSWOFLSA-N 0.000 description 1
- PPPYPWWJPYVOEC-UHFFFAOYSA-N (2-benzyl-7-methyl-1,3,4,6,8,8a-hexahydropyrrolo[1,2-a]pyrazin-7-yl)methanol Chemical compound C1CN2CC(C)(CO)CC2CN1CC1=CC=CC=C1 PPPYPWWJPYVOEC-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- GEZMEIHVFSWOCA-UHFFFAOYSA-N (4-fluorophenyl)methanol Chemical compound OCC1=CC=C(F)C=C1 GEZMEIHVFSWOCA-UHFFFAOYSA-N 0.000 description 1
- WGUPNYDZRWOBRU-UHFFFAOYSA-N (7-methyl-2,3,4,6,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-yl)methanol Chemical compound C1NCCN2CC(C)(CO)CC21 WGUPNYDZRWOBRU-UHFFFAOYSA-N 0.000 description 1
- AKCRYYRRJRHWPV-LMARGRMVSA-N (7S,8aS)-2-(5-fluoropyrimidin-2-yl)-1-methyl-7-phenoxy-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine Chemical compound O(C1=CC=CC=C1)[C@H]1C[C@@H]2N(CCN(C2C)C2=NC=C(C=N2)F)C1 AKCRYYRRJRHWPV-LMARGRMVSA-N 0.000 description 1
- QZBFYGAAFDCAEF-DLBZAZTESA-N (7r,8as)-7-[(4-fluorophenyl)methoxy]-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1CO[C@H]1CN2CCN(C=3N=CC(F)=CN=3)C[C@@H]2C1 QZBFYGAAFDCAEF-DLBZAZTESA-N 0.000 description 1
- JBYIGOQKVBBIAD-ZFWWWQNUSA-N (7s,8as)-2-(6-chloropyridazin-3-yl)-7-[(4-fluorophenoxy)methyl]-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1OC[C@@H]1CN2CCN(C=3N=NC(Cl)=CC=3)C[C@@H]2C1 JBYIGOQKVBBIAD-ZFWWWQNUSA-N 0.000 description 1
- KLJCVPLYXWZVKH-ICSRJNTNSA-N (7s,8as)-2-benzyl-7-(4-fluorophenoxy)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1O[C@@H]1CN2CCN(CC=3C=CC=CC=3)C[C@@H]2C1 KLJCVPLYXWZVKH-ICSRJNTNSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- LSEAAPGIZCDEEH-UHFFFAOYSA-N 2,6-dichloropyrazine Chemical compound ClC1=CN=CC(Cl)=N1 LSEAAPGIZCDEEH-UHFFFAOYSA-N 0.000 description 1
- DPZQQYROVRLQBF-UHFFFAOYSA-N 2-(5-chloropyridin-2-yl)-7-[(4-fluorophenoxy)methyl]-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1OCC1CN2CCN(C=3N=CC(Cl)=CC=3)CC2C1 DPZQQYROVRLQBF-UHFFFAOYSA-N 0.000 description 1
- ZENHWLJOYVQHGD-UHFFFAOYSA-N 2-(5-fluoropyrimidin-2-yl)-7-methyl-7-(phenoxymethyl)-1,3,4,6,8,8a-hexahydropyrrolo[1,2-a]pyrazine Chemical compound C1C2CN(C=3N=CC(F)=CN=3)CCN2CC1(C)COC1=CC=CC=C1 ZENHWLJOYVQHGD-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- WBKSENWJTAVSRR-HIFRSBDPSA-N 2-[(7S,8aS)-2-(5-chloropyridin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1[C@H]1CN2CCN(C=3N=CC(Cl)=CC=3)C[C@@H]2C1 WBKSENWJTAVSRR-HIFRSBDPSA-N 0.000 description 1
- YMRWNVBOCUVTSO-OCCSQVGLSA-N 2-[(7S,8aS)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1[C@H]1CN2CCN(C=3N=CC(F)=CN=3)C[C@@H]2C1 YMRWNVBOCUVTSO-OCCSQVGLSA-N 0.000 description 1
- UWTOFMVISAXLSN-HKUYNNGSSA-N 2-[4-[[(7s,8as)-2-(5-chloropyridin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-yl]methoxy]phenyl]ethanol Chemical compound C1=CC(CCO)=CC=C1OC[C@@H]1CN2CCN(C=3N=CC(Cl)=CC=3)C[C@@H]2C1 UWTOFMVISAXLSN-HKUYNNGSSA-N 0.000 description 1
- ZFTGXQKSOZHMFQ-WMZOPIPTSA-N 2-[4-[[(7s,8as)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-yl]methoxy]phenyl]ethanol Chemical compound C1=CC(CCO)=CC=C1OC[C@@H]1CN2CCN(C=3N=CC(F)=CN=3)C[C@@H]2C1 ZFTGXQKSOZHMFQ-WMZOPIPTSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- LFASPBCAVCUZES-UHFFFAOYSA-N 2h-pyrrolo[1,2-a]pyrazin-1-one Chemical compound O=C1NC=CN2C=CC=C12 LFASPBCAVCUZES-UHFFFAOYSA-N 0.000 description 1
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 1
- CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- GFRLTDWVFQHYCK-LALCZMHNSA-N 3-[[(7S,8aS)-2-(4-cyanophenyl)-1-methyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl]oxy]benzonitrile Chemical compound C(#N)C=1C=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=CC=C(C=C3)C#N)C2)C=CC=1 GFRLTDWVFQHYCK-LALCZMHNSA-N 0.000 description 1
- ZMOKVIBIPFLXIE-RHGDZWTLSA-N 3-[[(7S,8aS)-2-(5-fluoropyrimidin-2-yl)-1-methyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl]oxy]benzonitrile Chemical compound C(#N)C=1C=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=N3)F)C2)C=CC=1 ZMOKVIBIPFLXIE-RHGDZWTLSA-N 0.000 description 1
- SGHBRHKBCLLVCI-UHFFFAOYSA-N 3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 1
- TXSAQXRPPNYJLP-CNZKWUBKSA-N 4-[(7S,8aS)-7-(3-ethoxyphenoxy)-1-methyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]benzonitrile Chemical compound C(C)OC=1C=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=CC=C(C=C3)C#N)C2)C=CC=1 TXSAQXRPPNYJLP-CNZKWUBKSA-N 0.000 description 1
- NYMWMGHUIFYTLD-LALCZMHNSA-N 4-[(7S,8aS)-7-(4-cyanophenoxy)-1-methyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]benzonitrile Chemical compound C(#N)C1=CC=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=CC=C(C=C3)C#N)C2)C=C1 NYMWMGHUIFYTLD-LALCZMHNSA-N 0.000 description 1
- XENSJWUCTNSEHH-ZFWWWQNUSA-N 4-[(7s,8as)-7-(hydroxymethyl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl]benzonitrile Chemical compound C([C@@H]1C[C@@H](CN1CC1)CO)N1C1=CC=C(C#N)C=C1 XENSJWUCTNSEHH-ZFWWWQNUSA-N 0.000 description 1
- YOXMSGDZSNZUIB-RHGDZWTLSA-N 4-[[(7S,8aS)-2-(5-fluoropyrimidin-2-yl)-1-methyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl]oxy]benzonitrile Chemical compound C(#N)C1=CC=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=N3)F)C2)C=C1 YOXMSGDZSNZUIB-RHGDZWTLSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- NCUYVKXTIVARKV-OALUTQOASA-N 6-[(7s,8as)-7-[(3-cyanophenoxy)methyl]-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl]pyridine-3-carbonitrile Chemical compound N1=CC(C#N)=CC=C1N1C[C@@H]2C[C@H](COC=3C=C(C=CC=3)C#N)CN2CC1 NCUYVKXTIVARKV-OALUTQOASA-N 0.000 description 1
- ORIQLMBUPMABDV-UHFFFAOYSA-N 6-chloropyridine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)C=N1 ORIQLMBUPMABDV-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- GGGKIVRCBHWSRY-UHFFFAOYSA-N 7-[(4-fluorophenoxy)methyl]-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1OCC1CN2CCN(C=3N=CC(F)=CN=3)CC2C1 GGGKIVRCBHWSRY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- FYYOYUVESWYYCL-LBTAZEDMSA-N CC([C@H](C[C@@H](C1)OC(C=C2)=CC=C2F)N1CC1)N1C1=CC=CC(C#N)=C1 Chemical compound CC([C@H](C[C@@H](C1)OC(C=C2)=CC=C2F)N1CC1)N1C1=CC=CC(C#N)=C1 FYYOYUVESWYYCL-LBTAZEDMSA-N 0.000 description 1
- GBVKANOVPDCKCO-UHFFFAOYSA-N CC1C2N(CCN1C1=NC=C(C=N1)F)CCC2 Chemical compound CC1C2N(CCN1C1=NC=C(C=N1)F)CCC2 GBVKANOVPDCKCO-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 244000117054 Rungia klossii Species 0.000 description 1
- 235000002492 Rungia klossii Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 101000995081 Spinacia oleracea Kunitz-type serine protease inhibitor SOTI Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- VPZAUECHJCLODB-WDEREUQCSA-N [(7r,8as)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-yl] methanesulfonate Chemical compound C([C@@H]1C[C@H](CN1CC1)OS(=O)(=O)C)N1C1=NC=C(F)C=N1 VPZAUECHJCLODB-WDEREUQCSA-N 0.000 description 1
- PVYBIMHAUMUNAY-IRXDYDNUSA-N [(7s,8as)-2-(5-chloropyridin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-yl] benzoate Chemical compound N1=CC(Cl)=CC=C1N1C[C@@H]2C[C@H](OC(=O)C=3C=CC=CC=3)CN2CC1 PVYBIMHAUMUNAY-IRXDYDNUSA-N 0.000 description 1
- GZVACYBQWKBZPQ-RDJZCZTQSA-N [3-[[(7s,8as)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-7-yl]methoxy]phenyl]methanol Chemical compound OCC1=CC=CC(OC[C@@H]2CN3CCN(C[C@@H]3C2)C=2N=CC(F)=CN=2)=C1 GZVACYBQWKBZPQ-RDJZCZTQSA-N 0.000 description 1
- IZPZQHISQHRLFP-UHFFFAOYSA-J [Na+].[Na+].[Na+].[Na+].[Cl-].[Cl-].[Cl-].[Cl-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Cl-].[Cl-].[Cl-].[Cl-] IZPZQHISQHRLFP-UHFFFAOYSA-J 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- VRPROHKFPXNCLO-UHFFFAOYSA-N dimethyl 2-benzyl-1,3,5,6,7,7a-hexahydropyrrolo[1,2-c]imidazole-5,7-dicarboxylate Chemical compound C1C2C(C(=O)OC)CC(C(=O)OC)N2CN1CC1=CC=CC=C1 VRPROHKFPXNCLO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000005543 phthalimide group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 108010092215 spiroperidol receptor Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Toxicology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US898895P | 1995-12-21 | 1995-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ192998A3 true CZ192998A3 (cs) | 1999-05-12 |
Family
ID=21734893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ981929A CZ192998A3 (cs) | 1995-12-21 | 1996-11-06 | 2,7-Substituované oktahydropyrrolo[1,2-a]pyrazinové deriváty, meziprodukty pro jejich výrobu a farmaceutické prostředky na jejich bázi |
Country Status (33)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281216B1 (en) * | 1998-02-09 | 2001-08-28 | Duphar International Research B.V. | 2-aminoquinoline derivatives having d4-agonistic activity |
| EP0982030A3 (en) | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| CA2358865A1 (en) * | 1999-02-05 | 2000-08-10 | Pharmacia & Upjohn Company | Process to prepare (5r)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]-quinolin-2(1h)-one |
| DE60011858T2 (de) | 1999-09-10 | 2005-08-25 | Mitsubishi Jidosha Kogyo K.K. | Stufenloses Getriebe |
| HRP20020219A2 (en) * | 1999-09-14 | 2004-04-30 | Aventis Pharma Inc | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 antagonists |
| US7091199B1 (en) | 1999-09-14 | 2006-08-15 | Aventis Pharmaceuticals Inc. | Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists |
| US7125903B1 (en) | 1999-09-14 | 2006-10-24 | Aventis Pharmaceuticals Inc. | Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists |
| US7253165B2 (en) | 1999-09-14 | 2007-08-07 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists |
| MXPA04002492A (es) * | 2001-09-19 | 2004-05-31 | Merck Patent Ges Mit Baschrank | Uso novedoso de aminometil cromanos sustituidos. |
| TW200801005A (en) * | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Acetylenic piperazines as metabotropic glutamate receptor antagonists |
| US7728031B2 (en) * | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| US8669255B2 (en) * | 2011-09-29 | 2014-03-11 | Abbvie Inc. | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers |
| CN119112895A (zh) * | 2018-09-04 | 2024-12-13 | 康蒂内乌姆医疗公司 | 毒蕈碱性乙酰胆碱m1受体拮抗剂 |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4400511A (en) * | 1982-05-07 | 1983-08-23 | American Home Products Corporation | 2-Substituted octahydropyrrolo(1,2-A)-pyrazine-3-carboxylic acids |
| MX19222A (es) * | 1989-01-23 | 1993-12-01 | Pfizer | Agentes ansioliticos bis-aza-biciclicos |
| US5122515A (en) * | 1990-06-19 | 1992-06-16 | Smith Ross C | Nutrient composition containing dipeptides and method for administering the same |
| JP3058945B2 (ja) * | 1990-10-26 | 2000-07-04 | 三共株式会社 | Ｎ−（３，３−ジ置換アクリロイル）ピペラジン誘導体 |
| EP0665840A1 (en) * | 1992-10-23 | 1995-08-09 | MERCK SHARP & DOHME LTD. | Dopamine receptor subtype ligands |
| CA2146019A1 (en) * | 1992-10-23 | 1994-05-11 | Howard B. Broughton | Dopamine receptor subtype ligands |
| DE69530988T2 (de) * | 1994-08-05 | 2003-12-04 | Pfizer Inc., New York | Benzimidazolderivate mit dopaminerger wirkung |
| CA2200959C (en) * | 1994-09-30 | 2000-05-23 | Kishor A. Desai | 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives |
| US5576314A (en) * | 1994-12-12 | 1996-11-19 | Allelix Biopharmaceuticals Inc. | Bicyclic nonane and decane compounds having dopamine receptor affinity |
-
1996
- 1996-11-06 CA CA002240594A patent/CA2240594C/en not_active Expired - Fee Related
- 1996-11-06 NZ NZ320537A patent/NZ320537A/xx unknown
- 1996-11-06 SI SI9630343T patent/SI0874849T1/xx unknown
- 1996-11-06 DE DE69615404T patent/DE69615404T2/de not_active Expired - Fee Related
- 1996-11-06 CZ CZ981929A patent/CZ192998A3/cs unknown
- 1996-11-06 DK DK96935226T patent/DK0874849T3/da active
- 1996-11-06 RU RU98111742/04A patent/RU2162470C2/ru not_active IP Right Cessation
- 1996-11-06 AT AT96935226T patent/ATE205846T1/de not_active IP Right Cessation
- 1996-11-06 CN CN96199250A patent/CN1061350C/zh not_active Expired - Fee Related
- 1996-11-06 HU HU9900611A patent/HUP9900611A3/hu unknown
- 1996-11-06 JP JP52344697A patent/JP3204456B2/ja not_active Expired - Fee Related
- 1996-11-06 WO PCT/IB1996/001192 patent/WO1997023482A1/en not_active Application Discontinuation
- 1996-11-06 PT PT96935226T patent/PT874849E/pt unknown
- 1996-11-06 PL PL96327539A patent/PL327539A1/xx unknown
- 1996-11-06 IL IL12445396A patent/IL124453A0/xx unknown
- 1996-11-06 EP EP96935226A patent/EP0874849B1/en not_active Expired - Lifetime
- 1996-11-06 ES ES96935226T patent/ES2161377T3/es not_active Expired - Lifetime
- 1996-11-06 BR BR9612246A patent/BR9612246A/pt not_active Application Discontinuation
- 1996-11-06 AU AU73280/96A patent/AU704578B2/en not_active Ceased
- 1996-11-06 KR KR1019980704718A patent/KR100286786B1/ko not_active Expired - Fee Related
- 1996-11-06 TR TR1998/01161T patent/TR199801161T2/xx unknown
- 1996-11-08 TW TW085113669A patent/TW479058B/zh not_active IP Right Cessation
- 1996-12-16 PE PE1996000913A patent/PE25998A1/es not_active Application Discontinuation
- 1996-12-16 AR ARP960105715A patent/AR005102A1/es not_active Application Discontinuation
- 1996-12-18 TN TNTNSN96164A patent/TNSN96164A1/fr unknown
- 1996-12-18 MA MA24432A patent/MA26413A1/fr unknown
- 1996-12-19 GT GT199600101A patent/GT199600101A/es unknown
- 1996-12-20 ZA ZA9610781A patent/ZA9610781B/xx unknown
- 1996-12-20 CO CO96066997A patent/CO4480107A1/es unknown
- 1996-12-23 US US08/774,290 patent/US5714487A/en not_active Expired - Fee Related
-
1998
- 1998-06-19 NO NO982843A patent/NO309936B1/no unknown
- 1998-06-22 MX MX9805088A patent/MX9805088A/es unknown
-
2001
- 2001-10-30 GR GR20010401932T patent/GR3037060T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0587473B1 (fr) | Dérivés condensés de la pyridine comme inhibiteurs de l'effet des radicaux libres | |
| CZ192998A3 (cs) | 2,7-Substituované oktahydropyrrolo[1,2-a]pyrazinové deriváty, meziprodukty pro jejich výrobu a farmaceutické prostředky na jejich bázi | |
| AU2006274037B2 (en) | Isotopically substituted pantoprazole | |
| ZA200208969B (en) | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists. | |
| HRP970612A2 (en) | Process for substituted pyridines | |
| CZ285090B6 (cs) | 2,7-Disubstituovaný oktahydro-1H-pyrido-[1,2-a]pyrazinové deriváty a farmaceutické prostředky na jejich bázi | |
| JP6033788B2 (ja) | 置換されたメチルアミン、セロトニン５−ｈｔ６受容体アンタゴニスト、製造のための方法及びその使用 | |
| KR970005298B1 (ko) | 퀴놀린계 유도체와 그의 제조방법 | |
| KR20000022045A (ko) | 5-ht-2c 수용체 길항제로 유용한 인돌린 유도체 | |
| WO2023061492A1 (zh) | 2-氧代-3-氮杂双环[3.1.0]己烷衍生物 | |
| KR100497942B1 (ko) | 광학활성을 유발하는 7-피롤리딘 치환체를 갖는 광학활성의 퀴놀린 카르복실산 유도체 및 그의 제조방법 | |
| EP0556813A1 (en) | Amphoteric tricyclic compounds as antihistaminic and antiallergic agents | |
| US4438121A (en) | Isoquinoline amidoxime derivatives | |
| AU2004254226C1 (en) | 2,4-bis(trifluoroethoxy)pyridine compound and medicine containing the same | |
| US20110092540A1 (en) | Substituted n-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands | |
| US20050130983A1 (en) | Pyrrolopyrimidinone derivatives, process for preparation thereof, and method of using and composition comprising them | |
| JPH05255337A (ja) | ピロロ［３，２−ｅピラゾロ［１，５−ａピリミジン誘導体及びこれを含有する循環器系疾患治療剤 | |
| KR20000059756A (ko) | 피라졸로피리미디논 유도체와 이의 제조방법그리고 이의 용도 | |
| JP2000044560A (ja) | ベンゾキノリジン誘導体及びその製造方法 | |
| MXPA99004459A (en) | Process for substituted pyridines | |
| CZ169499A3 (cs) | Způsoby výroby substituovaných pyridinů | |
| EP1362858A1 (en) | Pyrrolopyrimidinone derivates, process of preparation and use | |
| KR19990006497A (ko) | 퀴놀론 카르복실산 유도체와 그 제조방법 | |
| WO1998056790A1 (en) | Dihydroimidazo[1,5-b]isoquinoline-1,3-diones as apoprotein b-100 inhibitors | |
| KR20010029698A (ko) | 광학활성을 유발하는 7-피롤리딘 치환체를 갖는광학활성의 퀴놀린 카르복실산 유도체 및 그의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD00 | Pending as of 2000-06-30 in czech republic |